Clinical Sarcoma Research (CSR) has launched with BioMed Central. CSR publishes the latest advances on rare solid cancers – sarcomas – and aims to be a platform for the sharing and discussion of clinical knowledge within this field.
Editors-in-Chief, Paola Casali and Angelo Dei Tos highlight networking as vital for dealing with rare cancers, and therefore the journal encourages clinicians and researchers to share their first-hand medical experiences and translational research with the global sarcoma community. It is also hoped that guidelines for better diagnosis, treatment and patient care can be developed through the sharing of clinical and translational research.
In clinical sarcoma studies, large datasets from patients are not always available due to the rarity of some sarcomas, and thus many high-quality studies are not published by mainstream journals. CSR recognizes this fact and welcomes studies reporting on smaller patient groups. This is exemplified by two research articles on osteosarcoma and hibernomas already published in CSR; both articles bring important contributions to our knowledge of these sarcomas, despite the smaller patient numbers involved in the studies.
Finally, in line with the ethos of the journal, readers are particularly invited to make use of the comments feature on individual articles to discuss the research presented within the article and add their own experiences.